BlackRock Health Sciences Opportunities Port Inst (SHSSX)
70.70
-0.23
(-0.32%)
USD |
Dec 30 2025
Returns Chart
Key Stats
| Net Expense Ratio | Total Assets Under Management | Weighted Average Dividend Yield | Turnover Ratio (Generic) |
|---|---|---|---|
| 0.84% | 6.565B | 1.32% | 43.00% |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized Total Returns Since Inception (Daily) | Max Drawdown (Since Inception) |
| -1.820B | 16.83% | Upgrade | Upgrade |
Basic Info
| Investment Strategy | |
| The Fund seeks long-term growth of capital. Under normal market conditions, the Fund invests at least 80% of total assets in equity securities, primarily common stock, of companies in health sciences and related industries. The Fund reserves the right to invest up to 20% of its total assets in other types of securities. |
| General | |
| Security Type | Mutual Fund |
| Equity Style | Large Cap Core |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Health/Biotechnology Funds |
| Fund Owner Firm Name | BlackRock |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
Net Fund Flows Versus Peer Group
1 Month
% Rank:
98
-129.73M
Peer Group Low
1.550B
Peer Group High
1 Year
% Rank:
98
-1.820B
-3.013B
Peer Group Low
514.53M
Peer Group High
3 Months
% Rank:
98
-537.77M
Peer Group Low
1.698B
Peer Group High
3 Years
% Rank:
97
-8.541B
Peer Group Low
312.13M
Peer Group High
6 Months
% Rank:
98
-1.345B
Peer Group Low
1.449B
Peer Group High
5 Years
% Rank:
98
-7.624B
Peer Group Low
2.983B
Peer Group High
YTD
% Rank:
98
-2.538B
Peer Group Low
561.96M
Peer Group High
10 Years
% Rank:
96
-13.08B
Peer Group Low
5.532B
Peer Group High
Date Unavailable
Risk
Performance Versus Peer Group
Annual Total Returns Versus Peers
As of December 31, 2025.
*Indicates data for the year is incomplete.
Asset Allocation
As of June 30, 2025.
| Type | % Net |
|---|---|
| Cash | 0.67% |
| Stock | 98.81% |
| Bond | 0.44% |
| Convertible | 0.00% |
| Preferred | 0.08% |
| Other | 0.00% |
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Eli Lilly & Co. | 10.88% | 1075.02 | -0.44% |
| Johnson & Johnson | 8.36% | 207.03 | 0.06% |
| Abbott Laboratories | 5.02% | 125.31 | -0.37% |
| AbbVie, Inc. | 3.96% | 228.50 | -0.54% |
| Thermo Fisher Scientific, Inc. | 3.69% | 579.52 | -0.67% |
| UnitedHealth Group, Inc. | 3.57% | 330.24 | -0.58% |
| Amgen, Inc. | 3.41% | 327.34 | -0.41% |
| Medtronic Plc | 3.36% | 96.08 | -0.60% |
| Gilead Sciences, Inc. | 2.94% | 122.75 | -0.35% |
| Intuitive Surgical, Inc. | 2.75% | 566.56 | -1.06% |
Fees & Availability
| Fees | |
| Actual 12B-1 Fee | -- |
| Actual Management Fee | 0.67% |
| Administration Fee | 2.22M% |
| Maximum Front Load | -- |
| Maximum Deferred Load | -- |
| Maximum Redemption Fee | 0.00% |
| General Availability | |
| Available for Insurance Product | No |
| Available for RRSP | No |
| Purchase Details | |
| Open to New Investors |
|
| Minimum Initial Investment | 2.00M None |
| Minimum Subsequent Investment | 0.00 None |
Basic Info
| Investment Strategy | |
| The Fund seeks long-term growth of capital. Under normal market conditions, the Fund invests at least 80% of total assets in equity securities, primarily common stock, of companies in health sciences and related industries. The Fund reserves the right to invest up to 20% of its total assets in other types of securities. |
| General | |
| Security Type | Mutual Fund |
| Equity Style | Large Cap Core |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Health/Biotechnology Funds |
| Fund Owner Firm Name | BlackRock |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
Fundamentals
| General | |
| Distribution Yield | -- |
| Dividend Yield TTM (12-29-25) | 0.40% |
| 30-Day SEC Yield | -- |
| 7-Day SEC Yield | -- |
| Number of Holdings | 10 |
| Stock | |
| Weighted Average PE Ratio | 35.94 |
| Weighted Average Price to Sales Ratio | 7.757 |
| Weighted Average Price to Book Ratio | 10.32 |
| Weighted Median ROE | 28.50% |
| Weighted Median ROA | 5.06% |
| ROI (TTM) | 6.76% |
| Return on Investment (TTM) | 6.76% |
| Earning Yield | 0.0374 |
| LT Debt / Shareholders Equity | 3.730 |
| Number of Equity Holdings | 10 |
As of June 30, 2025
Growth Metrics
| EPS Growth (1Y) | 18.01% |
| EPS Growth (3Y) | 5.44% |
| EPS Growth (5Y) | 9.73% |
| Sales Growth (1Y) | 13.18% |
| Sales Growth (3Y) | 9.99% |
| Sales Growth (5Y) | 12.78% |
| Sales per Share Growth (1Y) | 17.61% |
| Sales per Share Growth (3Y) | 10.99% |
| Operating Cash Flow - Growth Rate (3Y) | 2.72% |
As of June 30, 2025
Fund Details
Top Portfolio Holders
| Name | % Weight |
|---|---|
| Portfolio A | 5.00% |
| Portfolio B | 3.50% |
| Portfolio C | 2.25% |
Excel Add-In Codes
| Name: =YCI("M:SHSSX", "name") |
| Broad Asset Class: =YCI("M:SHSSX", "broad_asset_class") |
| Broad Category: =YCI("M:SHSSX", "broad_category_group") |
| Prospectus Objective: =YCI("M:SHSSX", "prospectus_objective") |
| To find the codes for any of our securities and financial metrics, see our Complete Excel Reference. |